



Serum Levels of Angiopoietin-Like Protein 6 (ANGPTL6) in Iranian Women with Polycystic Ovary Syndrome

Amir Azadi¹, Asma Kheirollahi², Fardin Amidi^{1,3}, Masoome Jabarpour⁴, Akram Vatannejad^{2*}, Maryam Shabani Nashtaei^{1,4*}, Nariman Moradi⁵, Soheila Ansari-pour⁶

1- Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

2- Department of Comparative Biosciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran

3- Department of Infertility, Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran

4- Department of Infertility, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

5- Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran

6- Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran

Abstract

Background: Infertility and miscarriage are common complications in women with PCOS, and may be linked with metabolic status and thyroid function. However, the role of ANGPTL6 in PCOS-related infertility and miscarriage remains underexplored. Study assessed serum ANGPTL6 levels in Iranian PCOS patients and its association with miscarriage, infertility, and thyroid dysfunction.

Methods: This case-control study included 116 PCOS women (58 with infertility, 58 with a history of miscarriage) and 58 non-PCOS controls. The measurement of ANGPTL6, adiponectin, fasting insulin, and other hormonal parameters were measured using ELISA. Parametric data were analyzed with t-tests and ANOVA, and non-parametric data with Mann-Whitney and Kruskal-Wallis tests. Correlations were assessed using Pearson and Spearman tests. Logistic regression was used predicted PCOS risk. A $p < 0.05$ was considered statistically significant.

Results: ANGPTL6 levels were significantly higher in the PCOS group (48.72 ± 21.41 ng/ml) and the PCOS-miscarriage subgroup (50.16 ± 19.57 ng/ml) compared to the non-PCOS group (41.56 ± 14.74 ng/ml). T4 levels were significantly lower in the PCOS group (2.5 ± 1.9 µg/dl) compared to controls (3.9 ± 4.6 µg/dl, $p < 0.001$). No significant correlation was found between ANGPTL6 and thyroid function tests. A positive correlation was observed between ANGPTL6 and adiponectin in the PCOS group ($p < 0.01$). Logistic regression showed a significant association between ANGPTL6 and the risk of PCOS (OR: 1.02, 95%CI: 1.002-1.038), even after adjusting for age, body mass index (BMI), and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR).

Conclusion: Elevated ANGPTL6 levels were correlated with PCOS. Future research is needed to explore the molecular pathways linking ANGPTL6 to PCOS and its interaction with metabolic biomarkers.

Keywords: Angiopoietin-like protein 6, Infertility, Miscarriage, Polycystic ovary syndrome.

To cite this article: Azadi A, Kheirollahi A, Amidi F, Jabarpour M, Vatannejad A, Shabani Nashtaei M, et al. Serum Levels of Angiopoietin-Like Protein 6 (ANGPTL6) in Iranian Women with Polycystic Ovary Syndrome. *J Reprod Infertil.* 2025;26(1):50-57. <https://doi.org/10.18502/jri.v26i1.18781>.

Introduction

Polycystic ovary syndrome (PCOS) is a heterogeneous metabolic disorder characterized by hyperandrogenism, polycystic ovaries, and

ovulatory dysfunction in women of reproductive age (1). PCOS significantly impacts the reproductive, metabolic, and psychological health of wom-

* Corresponding Authors:
Akram Vatannejad,
Department of Comparative
Biosciences, Faculty of
Veterinary Medicine,
University of Tehran,
Tehran, Iran

Maryam Shabani Nashtaei,
Department of Anatomy,
School of Medicine, Tehran
University of Medical
Sciences, Tehran, Iran and
Department of Infertility,
Shariati Hospital, Tehran
University of Medical
Sciences, Tehran, Iran
E-mail: vatannejad@ut.ac.ir,
maryam.shabani.n@gmail.com

Received: 3, Dec. 2024

Accepted: 26, Jan. 2025

en along with their overall quality of life. Symptoms of PCOS include irregular menstrual cycles, infertility, hirsutism, acne, obesity, and metabolic diseases (2). Although the exact etiology and pathophysiology of PCOS remain unclear, genetic, environmental, and lifestyle factors are believed to contribute to its development (3).

The pathophysiological features of PCOS can lead to adverse pregnancy outcomes, including an increased risk of miscarriage, pregnancy complications, and premature birth (4, 5). Studies suggest that infertility affects approximately 70% to 80% of women diagnosed with PCOS (6), while the prevalence of miscarriage ranges between 30% and 50% in this population (7). Given the regulatory role of thyroid hormones in metabolic processes, it is hypothesized that thyroid status might play a significant role in the pathogenesis of PCOS and its complications, including infertility and miscarriage. Notably, an elevated prevalence of thyroid disorders has been reported among women with PCOS compared to the general population (8-11). Recent studies indicate that members of the angiopoietin-like protein (ANGPTL) family may contribute to PCOS pathogenesis (12-15). ANGPTLs are orphan ligands with a coiled-coil domain and a fibrinogen-like domain that exhibit angiogenic effects (16, 17); however, their roles in metabolic regulation have been increasingly recognized (16).

Among these, ANGPTL6 also known as angiopoietin-related growth factor (AGF), has emerged as a hepatokine playing a pivotal role in glucose and lipid homeostasis and insulin sensitivity (18-20). Elevated ANGPTL6 levels have been linked to conditions such as preeclampsia (21), PCOS (15), type 2 diabetes mellitus (22), and metabolic syndrome (23), highlighting its potential significance in these contexts. In addition, a study suggests a potential correlation between ANGPTL6 levels and thyroid function, mediated by the influence of thyroid hormones on metabolic processes (24). Given the potential interrelationship among ANGPTL6, thyroid function, and metabolic processes, the purpose of the current study was to evaluate whether ANGPTL6 levels are associated with thyroid hormone profiles and metabolic dysfunction in women with PCOS. Recent findings suggest a potential association between ANGPTL6 and thyroid function, further highlighting its relevance in metabolic regulation. However, no prior studies have explored the relationship between ANGPTL6 levels and PCOS-related infer-

tility or miscarriage, particularly in Iranian women. Therefore, an attempt was made to assess the serum levels of ANGPTL6 in Iranian women with PCOS and its association with miscarriage and infertility. Moreover, the association between ANGPTL6 level with thyroid hormone profile was examined in both PCOS and non-PCOS groups.

Methods

Study population: A dataset comprising 116 patients diagnosed with PCOS and 58 non-PCOS individuals was included in this investigation. The sample size was determined based on previous similar studies, considering a significance level (α) of 0.05, a statistical power ($1-\beta$) of 0.8, and an effect size (f) of 0.25 for one independent variable ($k=1$). Based on these parameters, approximately 60 participants per group were estimated to provide sufficient power to detect statistically significant differences. The study participants were selected from Shariati Hospital affiliated with Tehran University of Medical Sciences (TUMS) and Avicenna Fertility Center affiliated to Avicenna Research Institute in Tehran. All participants aged between 20 and 40 years had a body mass index (BMI) in the range of 17 to 35 kg/m^2 . Women diagnosed with PCOS (26) who met the 2003 Rotterdam criteria were included in the study. The criteria are defined as the presence of at least two of the following three features: irregular menstrual cycles, polycystic ovary morphology, and hyperandrogenism (1). PCOS patients were categorized into two subgroups: those with PCOS-associated infertility ($n=58$) and individuals experiencing PCOS-related miscarriage ($n=58$). Infertile women were defined as those unable to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse. Recurrent miscarriage was characterized as the occurrence of a minimum of two consecutive pregnancy losses before 20 weeks of gestation. The control group consisted of 58 age- and BMI-matched women without PCOS to minimize confounding factors, thereby ensuring that the differences observed were due to PCOS rather than age or body composition. These women were screened to exclude any history of infertility, recurrent miscarriage, polycystic ovarian syndrome, hyperandrogenism or other endocrine disorders. This screening confirmed that the control group represented a healthy population without PCOS-related complications. Individuals with conditions such as hypertension, diabetes, coronary artery disease, cur-

rent pregnancy, lactation, or those on medication regimens that could potentially affect metabolism or endocrine functions were excluded from the study. In addition, PCOS patients who had received treatment for PCOS were excluded from the study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee, as well as the 1975 Helsinki Declaration, revised in 2008. Ethical approval for the research was obtained from the Ethics Committee of Tehran University of Medical Sciences (IR.TUMS.SHARIATI.REC.1402.032). Informed consent was obtained by means of a written informed consent form prior to beginning the study. Efforts were made to minimize biases in sample selection by ensuring that participants were selected based on specific criteria, such as age range, absence of underlying chronic diseases, and adherence to the inclusion and exclusion criteria.

Laboratory analysis: Following a 12 hr period of overnight fasting, venous blood samples were collected. Fasting blood glucose (FBG) and the lipid profile, encompassing triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were determined as reported previously (26). All participants were specifically instructed to fast for 12 hr prior to blood sample collection, and this fasting period was strictly enforced and confirmed by the research team. Furthermore, using the enzyme-linked immunosorbent assay (ELISA) method as detailed in previous studies (26, 27), follicle-stimulating hormone (FSH), luteinizing hormone (LH), free testosterone (FT), and fasting serum insulin were measured. Thyroid function was assessed by measuring free T4, thyroid-stimulating hormone (TSH), and anti-thyroid peroxidase antibody (Anti-TPO) using the ELISA method. The assessment of insulin resistance was performed utilizing the HOMA-IR formula: $[\text{FBG (mg/dL)}] \times [\text{fasting serum insulin } (\mu\text{U/ml})] / 405$ (28). The measurement of ANGPTL6 levels in the bloodstream was conducted using an ELISA kit (BioVendor, Czech Republic; catalog number: RAG001R), with intra- and inter-assay coefficients of variation (CV) of 3% and 6%, respectively. The detection limit of this assay is 1.2 ng/ml, as specified by the manufacturer.

Statistical analysis: The statistical analyses were conducted utilizing SPSS Statistics, version 16.0

(IBM Corp., USA). Before statistical analysis, the normal distribution of the continuous data was evaluated using the Shapiro–Wilk test. Parametric datasets, meeting normality and homogeneity assumptions, were analyzed using independent t-tests and ANOVA, with results presented as mean $\pm$ standard deviation (SD). For non-parametric datasets with skewed distributions, the Mann-Whitney U and Kruskal-Wallis tests were applied, with results expressed as median and interquartile range (IQR). Pearson and Spearman correlation analysis were employed to assess the correlation between ANGPTL6 and the other variables. To evaluate the ability of ANGPTL6 to predict the risk of PCOS occurrence, logistic regression analysis was performed. A two-tailed p-value of less than 0.05 was considered statistically significant.

Results

Participant's characteristics: Clinical characteristics and biochemical parameters of both the non-PCOS and PCOS groups, along with their respective subgroups, namely PCOS-infertile and PCOS-miscarriage, are presented in table 1. As reported in previous studies (29, 30), significant differences in insulin, HOMA-IR, TC, FSH, FT, and adiponectin levels were observed when comparing the PCOS group and/or PCOS subgroups with the non-PCOS groups. Additionally, T4 levels were significantly lower in the PCOS group ($2.5 \pm 1.9 \mu\text{g/dl}$), as well as in the PCOS-infertile and PCOS-miscarriage subgroups, compared to the control group ($3.9 \pm 4.6 \mu\text{g/dl}$).

As shown in figure 1, the level of ANGPTL6 was significantly higher in the PCOS group (48.72 ± 21.41) than in the non-PCOS group ($41.56 \pm 14.74 \text{ ng/ml}$), ($p=0.02$). A similar rise in ANGPTL6 level was also noted in the PCOS-miscarriage subgroup ($50.16 \pm 19.57 \text{ ng/ml}$) when compared to the control group ($p<0.05$), while the increase in PCOS-infertile women did not reach a significant level.

Clinical and biochemical parameters: The results of association between ANGPTL6 levels and the anthropometric, hormonal, and metabolic variables in both PCOS and non-PCOS groups are presented in table 2. ANGPTL6 showed a significant positive correlation with adiponectin in the PCOS group ($p<0.01$). However, no significant correlation was found between ANGPTL6 levels and thyroid function markers such as TSH, T4, and anti-TPO.

Table 1. Clinical characteristics of the study population

Variables	Non-PCOS group (n=58)	PCOS group (n=116)	p-value ^Δ	PCOS-infertile (n=58)	PCOS-miscarriage (n=58)	p-value ^{ΔΔ}
Age (years)	29.8±4.5	29.8±4	0.9	30±3.8	29.4±4.1 ^{b*}	0.5
BMI (kg/m ²)	25.4±3.1	25.8±3.6	0.3	25.6±4	26±3	0.5
FBG (mg/dl)	91.8±9.5	89.8±10.3	0.2	89±11.3	90.1±9.3	0.4
Insulin (μU/ml)	3 (2.1-4.1)	4.1 (2.7-7.1)	<0.0001	4.2 (3-7) ^{a**}	3.9 (2.1-8.1) ^{b**}	<0.0001
HOMA-IR	0.64 (0.45-0.96)	0.85 (0.59-1.5)	0.002	0.86 (0.62-1.3) ^{a*}	0.85 (0.53-1.8) ^{b*}	0.007
TG (mg/dl)	126.1±34.9	133.8±57.9	0.3	126.3±59.2	141.2±56.1	0.1
TC (mg/dl)	160±40.5	177.2±34.3	0.004	171±30.9	182.6±36.8 ^{b**}	0.004
LDL-C (mg/dl)	94.3±30.3	101.5±28.2	0.1	98.2±22.4	104.8±32.8	0.1
HDL-C (mg/dl)	46 (41.2-52)	44 (39-50)	0.1	43.5 (39-51)	44 (39-49)	0.3
FSH (IU/L)	8.2 (6.4-10.1)	6.4 (4.8-7.8)	<0.0001	6.4 (5.1-7.6) ^{a*}	6.4 (4.4-8.9)	0.005
LH (IU/L)	6.5 (4.8-8.3)	6.8 (4.7-8.7)	0.2	7 (4.4-10.2)	6.4 (5-8.5)	0.1
FT (pg/ml)	1.5±0.35	3.3±1.2	<0.0001	3.1±0.95 ^{a**}	3.4±1.4 ^{b**}	<0.0001
T4 (μg/dl)	3.9±4.6	2.5±1.9	<0.0001	1.7±2.4 ^{a**}	1.4±1 ^{b**}	<0.0001
TSH (mIU/L)	2.8±3.4	2.5±1.9	0.5	2.6±1.9	2.5±1.8	0.7
Anti-TPO (mIU/L)	19.4±43.2	54.4±189.8	0.06	65.6±246	43.2±109.2	0.2
Adiponectin (μg/ml)	5.1 (3.6-7.8)	2.5 (1.9-3.4)	<0.0001	2.4 (1.5-3.4) ^{a**}	2.8 (2-3.5) ^{b**}	<0.0001

The data are presented in mean ± standard deviation (SD) or median (Q1-Q3)

^Δ To determine the differences of variables between the non-PCOS and PCOS groups, an independent t-test was used

^{ΔΔ} To determine the differences of variables between the non-PCOS and PCOS sub-groups (infertile and miscarriage), a one-way ANOVA test with Tukey's corrections post hoc was used. Statistical significance was indicated as *p<0.05 and **p<0.01

a: Comparison between control group and PCOS-infertile subgroup

b: Comparison between control group and PCOS-miscarriage subgroup

c: Comparison between PCOS-infertile and PCOS-miscarriage subgroup

Abbreviations: BMI: Body Mass Index, FBG: Fasting Blood Glucose, FSH: Follicle-Stimulating Hormone, HDL-C: High-Density Lipoprotein Cholesterol, HOMA-IR: Homeostasis Model Assessment of Insulin Resistance, LDL-C: Low-Density Lipoprotein Cholesterol, LH: Luteinizing Hormone, PCOS: Polycystic Ovary Syndrome, TC: Total Cholesterol, TG: Triglyceride, Anti-TPO: Anti-thyroid Peroxidase Antibody, TSH: Thyroid Stimulating Hormone




Figure 1. Serum levels of ANGPTL6

* p<0.05 was considered statistically significant.

PCOS: Polycystic Ovarian Syndrome, ANGPTL6: Angiotensin-Like Protein 6

The levels of ANGPTL6 and PCOS risk: Logistic regression analysis was used to estimate the relationship between ANGPTL6 with the risk of PCOS and the results are shown in table 3. ANGPTL6 was found to have a significant association with PCOS risk, with an odds ratio of 1.02 (95%CI [1.002-1.038]) (p=0.025), suggesting that

higher ANGPTL6 levels are associated with a modestly increased risk of PCOS. This association remained significant even after adjusting for age, BMI, and Log HOMA-IR.

Discussion

While the traditional role of ANGPTL6 in angiogenesis was initially described (17), several studies have subsequently revealed a broader impact, encompassing energy metabolism and lipid control (17, 19, 31). Exploring the role of ANGPTL6 in metabolic networks may offer promising avenues for addressing metabolic disorders. To date, some studies have investigated the association between ANGPTL6 and metabolic disorders such as diabetes mellitus (22), obesity (32), and metabolic syndrome (23). According to research findings, it has been proposed that ANGPTL6 opposes obesity and its associated insulin resistance by

Table 2. Association of circulating ANGPTL6 levels and the anthropometric, hormonal, and metabolic variables

Variables	Non-PCOS group (n=58)	PCOS group (n=116)
Age	0.153	0.152
BMI	-0.032	-0.087
FBG	0.101	0.151
Log insulin	0.213	-0.064
Log HOMA-IR	0.147	-0.068
TG	0.225	0.079
Log HDL-C	-0.178	-0.173
LDL-C	0.05	0.142
TC	0.139	0.102
FT	0.071	-0.068
Log LH	-0.15	0.052
Log FSH	0.093	-0.006
Log adiponectin	-0.117	0.254**
T4	-0.097	-0.035
TSH	-0.021	-0.017
Anti-TPO	0.043	0.025

Pearson correlation coefficient is represented by r.

PCOS: Polycystic Ovary Syndrome, BMI: Body Mass Index, FBS: Fasting Blood Sugar, HOMA: Homeostasis Model Assessment, TG: Triglycerides, TC: Total Cholesterol, LDL-C: Low-Density Lipoprotein Cholesterol, HDL-C: High-Density Lipoprotein Cholesterol, FSH: Follicle-Stimulating Hormone, LH: Luteinizing Hormone, T: Free Testosterone, ANGPTL6: Angiopoietin-Like Protein 6

* p<0.05, ** p<0.01

enhancing overall energy expenditure within the body (31).

The current study revealed a significantly higher level of ANGPTL6 in PCOS patients compared to the non-PCOS group. Additionally, logistic regression results showed that increased ANGPTL6 levels were associated with an increased risk of PCOS. Consistent with our results, there are several studies that reported the increased level of ANGPTL6 in metabolic disorders (22, 23, 33). The elevation of ANGPTL6 levels in patients with PCOS and other metabolic disorders may imply the potential existence of ANGPTL6 resistance or

a compensatory mechanism in these conditions (22, 31, 33). Until now, only a few studies have investigated the levels of ANGPTL6 in women with PCOS. In a study conducted by Elci et al., ANGPTL6 levels in 30 obese and 30 non-obese women diagnosed with PCOS were evaluated. The results of the study showed a statistically significant increase in ANGPTL6 levels among obese and non-obese women with PCOS, as compared to the control subjects (34). They also reported that the increased level of ANGPTL6 was significantly higher in the obese PCOS group than the non-obese PCOS group (34). In another study in China involving 35 women with PCOS and 30 healthy control women, PCOS women showed significantly higher levels of ANGPTL6 compared to non-PCOS subjects (15). These findings suggest that ANGPTL6 may play a key role in the metabolic disturbances observed in PCOS, potentially through mechanisms such as ANGPTL6 resistance or compensatory responses.

To the best of our knowledge, this is the first study that evaluated the association between ANGPTL6, infertility, and miscarriage in Iranian women with PCOS. It was shown that the PCOS-miscarriage subgroup had a significantly higher level of ANGPTL6 in comparison to the non-PCOS group. Although the scientific community has not reached a consensus on the precise mechanism of miscarriage in PCOS patients, several factors have been proposed as potential contributors. These include the hypersecretion of luteinizing hormone, hyperandrogenemia, hyperinsulinemia, obesity, and abnormalities in folliculogenesis (35). According to the results of the present study and other studies, it seems that elevated levels of ANGPTL6 along with alteration in other metabolic factors may play a pivotal role in the pathogenesis of both PCOS and PCOS-related miscarriages.

The significant association between ANGPTL6 levels and PCOS risk suggests that ANGPTL6

Table 3. The odds ratio of PCOS status according to circulating ANGPTL6 levels using logistic regression analysis

Model	OR	95%CI		p-value
		Minimum	Maximum	
Unadjusted model	1.02	1.002	1.038	0.025
Adjusted model for age and BMI	1.021	1.003	1.039	0.02
Adjusted model for age, BMI, and Log HOMA-IR	1.027	1.027	1.049	0.02

PCOS: Polycystic Ovary Syndrome, BMI: Body Mass Index, HOMA-IR: Homeostasis Model Assessment of Insulin Resistance, CI: Confidence Interval

could serve as a potential biomarker for early detection of PCOS, especially in women at risk for recurrent miscarriage. In addition, targeting ANGPTL6 could be explored as a therapeutic approach, potentially modulating metabolic and reproductive dysfunctions associated with PCOS. Further studies are needed to assess whether ANGPTL6-targeted interventions could be effective in improving clinical outcomes in PCOS patients.

Insulin resistance and dyslipidemia, two main features of metabolic syndrome (MetS), appear to have important pathophysiological implications for human well-being, particularly in connection to female reproductive potential (36). MetS is a chronic inflammatory state that, when coupled with dyslipidemia, has been linked to poor reproductive consequences (37, 38). Additionally, metabolic disorders have been linked to decreased fertility in women diagnosed with PCOS (39). In the present study, ANGPTL6 levels in the PCOS-infertile subgroup were not significantly elevated compared to controls. Drawing from the observed correlation between MetS and infertility and the significant associations between ANGPTL6 levels and metabolic disorders, it was postulated that the infertile subgroup would demonstrate elevated concentrations of ANGPTL6. A larger sample size may have been necessary in order to detect and analyze this significant discrepancy.

Although some studies have evaluated thyroid status in PCOS women (11, 40, 41), no research has investigated the relationship between ANGPTL6 levels and thyroid function. Our results showed that free T4 levels were significantly lower in PCOS women. In line with this result, Abdelsalam and Ibrahim reported a significant decrease in T4 in PCOS women as compared to the controls (42). However, there was no significant correlation between the levels of ANGPTL6 and TSH, free T4, and TPO in both PCOS and non-PCOS individuals. In this regard, a study by Lim et al. in 2015 showed the association of ANGPTL6 with TSH and free T4 levels. They also reported an increased level of ANGPTL6 in hypothyroid patients (24). The variation in findings between our study and that of Lim et al. may be attributed to differences in sample size, the characteristics of the studied populations, and possibly the methods used to measure ANGPTL6. Our study population consisted of PCOS women with varying clinical features, while Lim et al. focused

on hypo/hyperthyroid patients, which could explain the observed discrepancy in results.

The present study is the first comprehensive investigation evaluating ANGPTL6 levels in Iranian women with PCOS and its association with miscarriage and infertility. However, several limitations should be acknowledged. Firstly, the case-control design of the study limits the ability to establish a definitive causal relationship between ANGPTL6 and PCOS. Secondly, the study's focus on an Iranian population may limit the generalizability of the findings to other populations. The small sample size also restricts the statistical power of the results. Additionally, the absence of longitudinal data and causal analysis, as well as the lack of specific PCOS phenotypes for more detailed analysis, further constrains the interpretation of the findings.

Conclusion

This study demonstrated that serum level of ANGPTL6 is enhanced in PCOS group, as well as PCOS-miscarriage subgroup, when compared to non-PCOS. No significant association was found between ANGPTL6 and thyroid function tests. Thus, it can be concluded that ANGPTL6 levels might influence the metabolic status in PCOS patients, regardless of thyroid function. Moreover, ANGPTL6 could serve as a potential biomarker for PCOS, which may enhance the early detection and management of the condition. Further research is needed to explore the mechanisms linking ANGPTL6 with the pathogenesis of PCOS and to assess its clinical utility in PCOS management, particularly in diverse populations and clinical settings.

Acknowledgement

The authors are grateful to the Medical Research Council of Tehran University of Medical Sciences for supporting this project.

Funding: This study was supported by the Tehran University of Medical Sciences (grant number: 1402-2-101-67472).

Conflict of Interest

The authors declare that they have no competing interests.

References

1. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related

- to polycystic ovary syndrome. *Fertil Steril*. 2004;81(1):19-25.
2. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. *J Clin Endocrinol Metab*. 1999;84(6):1897-9.
3. Siddiqui S, Mateen S, Ahmad R, Moin S. A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS). *J Assist Reprod Genet*. 2022;39(11):2439-73.
4. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GHA, Fauser BCJM, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. *Hum Reprod Update*. 2006;12(6):673-83.
5. Bahri Khomami M, Joham AE, Boyle JA, Piltonen T, Silagy M, Arora C, et al. Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity—A systematic review, meta-analysis, and meta-regression. *Obes Rev*. 2019;20(5):659-74.
6. Melo AS, Ferriani RA, Navarro PA. Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. *Clinics (Sao Paulo)*. 2015;70(11):765-9.
7. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. *J Clin Endocrinol Metab*. 2002;87(2):524-9.
8. Sinha U, Sinharay K, Saha S, Longkumer TA, Baul SN, Pal SK. Thyroid disorders in polycystic ovarian syndrome subjects: A tertiary hospital based cross-sectional study from Eastern India. *Indian J Endocrinol Metab*. 2013;17(2):304-9.
9. Benetti-Pinto CL, Piccolo VR, SB, Garmes HM, Juliato CRT. Subclinical hypothyroidism in young women with polycystic ovary syndrome: an analysis of clinical, hormonal, and metabolic parameters. *Fertil Steril*. 2013;99(2):588-92.
10. Janssen OE, Mehlmauer N, Hahn S, Öffner AH, Gärtner R. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. *Eur J Endocrinol*. 2004;150(3):363-9.
11. Singla R, Gupta Y, Khemani M, Aggarwal S. Thyroid disorders and polycystic ovary syndrome: An emerging relationship. *Indian J Endocrinol Metab*. 2015;19(1):25-9.
12. Jiang Q, Miao R, Wang Y, Wang W, Zhao D, Niu Y, et al. ANGPTL4 inhibits granulosa cell proliferation in polycystic ovary syndrome by EGFR/JAK1/STAT3-mediated induction of p21. *FASEB J*. 2023;37(2):e22693.
13. Vatannejad A, Salimi F, Moradi N, Fouani FZ, Zandieh Z, Ansaripour S, et al. Evaluation of angiopoietin-like protein 3 (ANGPTL3) levels in polycystic ovary syndrome. *Life Sci*. 2020;263:118595.
14. Jiang Q, Pan Y, Li P, Zheng Y, Bian Y, Wang W, et al. ANGPTL4 expression in ovarian granulosa cells is associated with polycystic ovary syndrome. *Front Endocrinol (Lausanne)*. 2022;12:799833.
15. Boztosun A, Deveci K, Kiliçli F, Söylemez MS, Muhtaroglu S, Müderris İİ. Serum levels of angiopoietin-related growth factor (AGF) are increased in polycystic ovary syndrome. *J Investig Med*. 2012;60(5):813-7.
16. Carbone C, Piro G, Merz V, Simionato F, Santoro R, Zecchetto C, et al. Angiopoietin-like proteins in angiogenesis, inflammation and cancer. *Int J Mol Sci*. 2018;19(2):431.
17. Hato T, Tabata M, Oike Y. The role of angiopoietin-like proteins in angiogenesis and metabolism. *Trends Cardiovasc Med*. 2008;18(1):6-14.
18. Oike Y, Yasunaga K, Suda T. Angiopoietin-related/angiopoietin-like proteins regulate angiogenesis. *Int J Hematol*. 2004;80(1):21-8.
19. Oike Y, Akao M, Yasunaga K, Yamauchi T, Morisada T, Ito Y, et al. Angiopoietin-related growth factor antagonizes obesity and insulin resistance. *Nat Med*. 2005;11(4):400-8.
20. Valencia-Martínez A, Schaefer-Graf U, Amusquivar E, Herrera E, Ortega-Senovilla H. Relationship of ANGPTL6 with neonatal glucose homeostasis and fat mass is disrupted in gestational diabetic pregnancies. *J Clin Endocrinol Metab*. 2022;107(10):e4078-85.
21. Stepan H, Ebert T, Schrey S, Reisenbüchler C, Stein S, Lossner U, et al. Serum levels of angiopoietin-related growth factor are increased in preeclampsia. *Am J Hypertens*. 2009;22(3):314-8.
22. Ebert T, Bachmann A, Lossner U, Kratzsch J, Blüher M, Stumvoll M, et al. Serum levels of angiopoietin-related growth factor in diabetes mellitus and chronic hemodialysis. *Metabolism*. 2009;58(4):547-51.
23. Namkung J, Koh SB, Kong ID, Choi JW, Yeh BI. Serum levels of angiopoietin-related growth factor are increased in metabolic syndrome. *Metabolism*. 2011;60(4):564-8.
24. Lim JA, Kim HJ, Ahn HY, Park KU, Yi KH, Park DJ, et al. Influence of thyroid dysfunction on serum levels of angiopoietin-like protein 6. *Metabolism*. 2015;64(10):1279-83.

25. Hajian-Tilaki K. Sample size estimation in diagnostic test studies of biomedical informatics. *J Biomed Inform.* 2014;48:193-204.
26. Shanaki M, Moradi N, Fadaei R, Zandieh Z, Shabani P, Vatannejad A. Lower circulating levels of CTRP12 and CTRP13 in polycystic ovarian syndrome: irrespective of obesity. *PloS One.* 2018;13(12):e0208059.
27. Kheirollahi A, Teimouri M, Karimi M, Vatannejad A, Moradi N, Borumandnia N, et al. Evaluation of lipid ratios and triglyceride-glucose index as risk markers of insulin resistance in Iranian polycystic ovary syndrome women. *Lipids Health Dis.* 2020;19(1):235.
28. Esteghamati A, Ashraf H, Khalilzadeh O, Zandieh A, Nakhjavani M, Rashidi A, et al. Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). *Nutr Metab (Lond).* 2010;7:26.
29. Sadeghi A, Fadaei R, Moradi N, Fouani FZ, Roozbehkia M, Zandieh Z, et al. Circulating levels of C1q/TNF- α -related protein 6 (CTRP6) in polycystic ovary syndrome. *IUBMB Life.* 2020;72(7):1449-59.
30. Fouani FZ, Fadaei R, Moradi N, Zandieh Z, Ansaripour S, Yekaninejad MS, et al. Circulating levels of Meteorin-like protein in polycystic ovary syndrome: a case-control study. *PloS One.* 2020;15(4):e0231943.
31. Kadomatsu T, Tabata M, Oike Y. Angiopoietin-like proteins: emerging targets for treatment of obesity and related metabolic diseases. *FEBS J.* 2011;278(4):559-64.
32. Mirzaei K, Hossein-Nezhad A, Chamari M, Shahbazi S. Evidence of a role of ANGPTL6 in resting metabolic rate and its potential application in treatment of obesity. *Minerva Endocrinol.* 2011;36(1):13-21.
33. Ebert T, Kralisch S, Loessner U, Jessnitzer B, Stumvoll M, Fasshauer M, et al. Relationship between serum levels of angiopoietin-related growth factor and metabolic risk factors. *Horm Metab Res.* 2014;46(10):685-90.
34. Elci E, Kaya C, Cim N, Yildizhan R, Elci GG. Evaluation of cardiac risk marker levels in obese and non-obese patients with polycystic ovaries. *Gynecol Endocrinol.* 2017;33(1):43-7.
35. van der Spuy ZM, Dyer SJ. The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome. *Best Pract Res Clin Obstet Gynaecol.* 2004;18(5):755-71.
36. Cardozo E, Pavone ME, Hirshfeld-Cytron JE. Metabolic syndrome and oocyte quality. *Trends Endocrinol Metab.* 2011;22(3):103-9.
37. Canello R, Clément K. Is obesity an inflammatory illness? role of low-grade inflammation and macrophage infiltration in human white adipose tissue. *BJOG.* 2006;113(10):1141-7.
38. Catov JM, Bodnar LM, Ness RB, Barron SJ, Roberts JM. Inflammation and dyslipidemia related to risk of spontaneous preterm birth. *Am J Epidemiol.* 2007;166(11):1312-9.
39. He Y, Lu Y, Zhu Q, Wang Y, Lindheim SR, Qi J, et al. Influence of metabolic syndrome on female fertility and in vitro fertilization outcomes in PCOS women. *Am J Obstet Gynecol.* 2019;221(2):138.e1-138.e12.
40. Kachuei M, Jafari F, Kachuei A, Keshteli AH. Prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. *Arch Gynecol Obstet.* 2012;285(3):853-6.
41. Morgante G, Musacchio MC, Orvieto R, Massaro MG, De Leo V. Alterations in thyroid function among the different polycystic ovary syndrome phenotypes. *Gynecol Endocrinol.* 2013;29(11):967-9.
42. Abdelsalam KEA, Ibrahim W. Relationship between TSH, T4, T3 and prolactin in overweight and lean sudanese PCOS patients. *Int J Biomed Res.* 2015;6(2):108-12.